PTC Therapeutics Proposes $500M 2031 Convertible Notes to Refinance 2026 Debt and Buy Back $50M Stock
PTCT•PTC Therapeutics plans a private placement of $500 million convertible senior notes due 2031 with a $50 million overallotment option. Net proceeds will repay its 1.5% convertible notes due 2026 and fund approximately $50 million of common stock buybacks, potentially affecting share supply and conversion pricing.
1. Offering Details
PTC Therapeutics is offering $500 million aggregate principal amount of convertible senior notes due 2031 in a private placement, with a 13-day overallotment option for up to $50 million additional notes. These notes will accrue semiannual interest and be general senior unsecured obligations convertible into cash, stock, or both at the company’s election.
2. Use of Proceeds
PTC plans to apply net proceeds to repurchase or repay its 1.5% convertible senior notes maturing in 2026, execute approximately $50 million in common stock buybacks via privately negotiated transactions, and allocate any remaining funds to general corporate purposes.
3. Market Impact
Concurrent note and share repurchases by initial note investors could compress share supply and influence PTCT's stock price, potentially raising the effective conversion price. Unwinding of convertible arbitrage positions may further drive share purchases, affecting market dynamics before and after note pricing.
